

unrivaled wisdom

HEALTHCARE TECHNOLOGY & TECH-ENABLED SERVICES

WEEK-IN-REVIEW | FEBRUARY 11, 2022

Ryan Stewart

HS

Managing Director Head of Healthcare Technology & Tech-Enabled Services (o) 212.508.1610 | (m) 612.227.2132 Ryan.Stewart@solomonpartners.com

Eric Bormel

Vice President Healthcare Technology & Tech-Enabled Services (o) 646.378.4063 | (m) 410.404.0204 Eric.Bormel@solomonpartners.com

EJ Salamone

Associate Healthcare Technology & Tech-Enabled Services (o) 646.708.8476 | (m) 203.482.6768 EJ.Salamone@solomonpartners.com



Week-in-Review: At-a-Glance

Key Highlights

Solomon Partners Healthcare Tech Group Year in Review Now Available – The Solomon Partners 2021 Healthcare Technology & Tech-Enabled Services 2021 Year in Review is available through the following link.

Signify Health announces \$250 million acquisition of Caravan Health – Signify Health, a value-based care healthcare platform, announced its acquisition of Caravan Health, a startup focused on helping providers transition into accountable care organizations, for \$250 million. Signify Health operates a healthcare platform that utilizes analytics, technology, and healthcare provider networks in the United States. Caravan Health provides value-based care advisory services to hospitals and physicians. The acquisition will help Signify diversify its strategy, create an "end-to-end suite of value-based care" tools, drive growth and bring financial benefits through expanding the addressable market. Payment for the transaction will include \$190 million in cash, \$60 million in stock, and a contingent payment of up to \$50 million based on performance.

McKesson Ventures-backed Koneksa announces \$45 million Series C – Koneksa, a digital biomarker startup, announced its \$45 million Series C led by AyurMaya Capital Management (an affiliated fund of Matrix Capital Management), with participation from Takeda Ventures, Velocity Capital, McKesson Ventures, Merck Global Health Innovation Fund, Spring Mountain Capital and Waterline Ventures. Koneksa provides an algorithm-based platform that analyzes and integrates raw data from wearables and sensors. The company plans to use the new cash to grow its digital-biomarker platform and the self-service tools in its clinical-data-integration products. It also plans to build out its science team, including adding its first chief medical officer. To date, Koneksa has raised \$65 million.

Oaktree Capital Management-backed HealthCare.com announces \$31.5 million Series C – HealthCare.com, an insurtech provider, announced its \$31.5 million Series C led by Hildred Capital Management. HealthCare.com's platform allows consumers to input information about their insurance needs, matches them to plans and helps them enroll in coverage. The company plans to use the new cash to accelerate the development of its AI platform. To date, Healthcare.com has raised \$247 million.

Contour Venture Partners-backed Trialjectory announces \$20 million Series A – Trialjectory, a company that matches cancer patients to clinical trials, announced its \$20 million Series A led by Insight Partners with participation from JAL Ventures, Contour Venture Partners, Rho Capital and TIA Ventures. Trialjectory offers an Al-enabled platform that matches cancer patients to open clinical trials. The company will use the new cash to define a new market category focused on delivering personalized, treatment decision-support and a new way for pharma to offer an authentic, patient-centered experience. To date, Trialjectory has raised \$28 million.

HealthQuest Capital-backed Thirty Madison announces acquisition of Nurx – Thirty Madison, a digital health company for patients with hair loss, migraines and other chronic conditions, announced its acquisition of Nurx, a female-focused virtual care company. Thirty Madison operates condition-specific brands that provide end-to-end care, including specialist-level telehealth, personalized treatment delivery, and ongoing condition management. Nurx operates a platform intended for women that allows users to request medication without the need to visit a doctor, hospital, or consult a medical professional. The deal seeks to expand Thirty Madison's existing offerings, allowing the combined company to treat a greater range of conditions on a single platform. The combined company will support over 750,000 active patients.

Other Mergers & Acquisitions Updates

Acquirer	Target	Ent. Value (\$M)
doximity	AMION	\$82.5
O thrive	PELITAS	ND
yprime	tryl	ND
	klara	ND


Other Equity Financing Updates

Company	Lead Investor(s)	Financing (\$M)
€ ¹ expressable	F / PRIME CAPITAL PARTNERS	\$15
visu well		\$10
balanced		\$6.5

		Hea	althcare Techno	logy & Tech-En	abled Services	Weekly Perfor	mance		
		<u>Market Leaders</u>					Market Laggard	<u>ls</u>	
P ELOTON	bright	doximity	s agilon	Science 37	Go Health ^e	eHealth	🕑 Craneware®		🤣 amwell
54.7%	41.5%	▲ 32.0%	▲ 28.9%	16.2%	▼ (16.0%)	▼ (12.3%)	▼ (8.4%)	v (7.5%)	v (4.1%)



Week-in-Review: Healthcare Technology & Tech-Enabled Services Stock Performance as of February 10, 2022



SOLOMON SOLOMON

Week-in-Review: Industry and Company News



Industry and Company News

Al-powered scheduling can boost clinician engagement, reduce burnout

"Research presented this past week at ASA Advance 2022, the Anesthesiology Business Event, found that artificial intelligence-based scheduling can play a significant role in reducing burnout and improving physician engagement. Six months after the anesthesiology department at Ochsner Health in New Orleans implemented its new AI scheduling system, the average engagement scores of 60 anesthesiologists increased from 3.3 to 4.2 out of 5, said researchers – one of the largest improvements in the Ochsner Health system. Oschner's previous scheduling system had relied on an Excel spreadsheet, which allowed for one or two variations after accounting for day-off requests, call schedules and fair allocation of early versus late days. The study found that the AI-based scheduling tool, in comparison, provided both flexibility and predictability, in part by increasing vacation days and reducing ungranted vacation days. This led to significantly improved engagement scores from anesthesiologists within half a year – suggesting, in turn, a better working relationship between the organization and clinicians, said researchers" <u>Healthcare IT News | 2/4/22</u>

Labcorp launches new digital diagnostics platform

"Diagnostics giant Labcorp is stepping deeper into the digital health space with the launch of Labcorp OnDemand, an online platform where users can order tests and possibly collect samples at home. Patients choose tests through the platform and a physician can approve and review requests without a required doctor's visit. Some tests allow patients to collect samples in their homes, while others require them to go to a Labcorp collection center. Patients can then view results through the platform. Some of the tests available through Labcorp OnDemand include colorectal cancer screenings, COVID-19 PCR tests, cholesterol and lipid panels, general health blood tests, pregnancy tests, and sexual health screenings. The clinical lab company said it plans to make more test kit options available through physicians health plans and employers later this year. Labcorp is pitching the platform as a more convenient way for patients to access blood tests, as well as an expansion of their digital health offerings. This isn't Labcorp's first foray into digital and at-home services. The new platform replaces Pixel by Labcorp, a similar offering that launched in 2018, with four screens for general wellness, heart health, diabetes and colorectal cancer."

CVS teams up with decentralized clinical trial company Medable

"Retail giant CVS is teaming up with unicorn digital clinical trial company Medable on a new initiative to grow clinical trial engagement at the former's CVS MinuteClinics. The new effort will be run by the recently launched CVS Health Clinical Trial Services, and use Medable's platform to help enroll patients and conduct clinical trials. The pair are pitching this program as a way to help boost diversity in clinical trials by tapping into Medable's decentralized trial platform and CVS' geographical reach. CVS' new clinical trial service launched in May 2021 and is aimed at working with life science industries to boost research and real-world evidence. CVS said that the partnership with Medable will help it continue to develop its efforts in precision patient recruitment, clinical trial delivery and real-world evidence generation. Investors have also taken an interest in Medable. In October, the company closed a \$304 million Series D round led by Blackstone Growth, Tiger Global and GSR Ventures. That round brought the company's valuation to \$2.1 billion." *MobiHealthNews* 1 2/7/22

Industry and Company News (Cont'd)

Humana and Array Behavioral Care launch behavioral health services partnership

"Humana has entered into a partnership with Array Behavioral Care, a national telehealth practice specializing in behavioral health, with the latter slated to provide behavioral telehealth services to Humana Medicare Advantage individual and group members nationwide in 2022. Array AtHome's virtual psychiatry and counseling services are now available to about five million Medicare Advantage members, effective Jan. 1. Since 2016, Array has served Humana members as a covered benefit through partnerships with primary care providers, integrating behavioral care into their clinics and practices. Humana, recognizing a growing need for behavioral healthcare, has expanded its behavioral health strategy and selected Array AtHome to be one of its direct-to-patient behavioral telehealth providers, citing research showing that 25% of Medicare beneficiaries live with some form of mental illness. The insurer expects that Array AtHome will make it easier for patients to get the requisite help through a large network of qualified clinicians and high appointment availability." *Healthcare Finance* 1 2/8/22

Anthem rolling out virtual primary care to plans in 11 states

• "Anthem will make virtual primary care available to eligible members of its commercial health plans in 11 states, the insurer announced Tuesday. The expansion will roll out the offering to fully insured plans and select large group administrative services clients in Colorado, Connecticut, Georgia, Indiana, Kentucky, Missouri, Nevada, New York, Ohio, Virginia and Wisconsin, the company said. Eligible members can access a virtual care team that will conduct an initial health check-in and then craft a personalized care plan. The insurer is expecting a significant number of its administrative services clients to adopt the platform over the course of this year. The care team will offer the member services aimed at improving their health and wellbeing at little or no cost, Anthem said. The virtual primary care options will be available through Anthem's Sydney Health app. Through Sydney, members can connect with providers 24/7 via a secure text chat for urgent care needs as well as to schedule appointments and followups. The initial check-in visit will be conducted via video, and members can also access other services including prescription refills, referrals and preventative screenings." *Fierce Healthcare* 12/8/22

Cadence teams up with Community Health Systems to bring RPM platform for chronic care to thousands

• "A whopping six in ten Americans suffer from at least one chronic disease, costing the U.S. healthcare system \$1.65 trillion each year. Chronic care management startup Cadence has inked another partnership to support those patients while cutting down total spend. Community Health Systems will deliver Cadence's remote patient monitoring and virtual care solution to its thousands of patients nationwide, the companies announced Thursday. The platform will be available across Community Health Systems' network of affiliated hospitals and physician offices in 16 states, and per Cadence's design, will initially support patients with hypertension, heart failure, diabetes and chronic obstructive pulmonary disease. The digital health startup has seen exponential growth since its launch in August, reaching unicorn status in December with \$100 million in series B funding. Cadence's platform collects vital signs and wellness data and integrates that information with the patient's medical history to create personalized daily care plans. The model aims to reduce the likelihood of hospitalizations, decreasing the cost of care while keeping patients engaged." *Fierce Healthcare* | 2/10/22


Stock Price Performance & Valuation



	Price	Stock Price Performance		Equity	Enterprise	Revenue	% Rev	Growth	EV / Rev	venue	Gross	Margin	EBITDA Margin		EV / EBITDA		Price / EPS					
Company Name	2/10/22	Weekly	1-Month	3-Month	6-Month	LTM	YTD	Value	Value	CY2022	CY2021	CY2022	CY2022	CY2023	CY2022	CY2023	CY2022	CY2023	CY2022	CY2023	CY2022	CY2023
Payer-Tech																						
Change Healthcare	\$20.40	6.7%	(4.7%)	(4.7%)	(4.4%)	(14.2%)	(4.6%)	\$6,331	\$10,825	\$3,597	6.3%	6.0%	3.0 x	2.8 x	NA	NA	31.0%	32.1%	9.7 x	8.8 x	12.1 x	10.8 x
Convey Health	7.08	(3.1%)	(8.6%)	(2.2%)	(14.7%)	IPO	(15.3%)	518	672	395	17.0%	16.5%	1.7 x	1.5 x	43.3%	43.9%	20.2%	20.4%	8.4 x	7.2 x	20.8 x	15.4 x
eHealth	16.40	(12.3%)	(37.5%)	(46.3%)	(66.3%)	(72.1%)	(35.7%)	468	466	587	7.5%	14.1%	0.8 x	0.7 x	99.4%	99.0%	4.0%	8.1%	20.1 x	8.6 x	NM	NM
GoHealth	1.99	(16.0%)	(34.5%)	(57.7%)	(76.9%)	(86.6%)	(47.5%)	227	1,406	1,495	21.2%	21.7%	0.9 x	0.8 x	79.6%	80.5%	27.8%	27.8%	3.4 x	2.8 x	2.4 x	1.8 x
MultiPlan Corporation	4.13	4.6%	2.0%	9.8%	(40.2%)	(47.9%)	(6.8%)	2,636	7,304	1,244	11.4%	6.0%	5.9 x	5.5 x	NA	NA	74.2%	75.0%	7.9 x	7.4 x	19.0 x	13.6 x
Ontrak	2.87	2.9%	(38.0%)	(66.3%)	(89.4%)	(96.9%)	(54.4%)	62	34	47	(44.1%)	47.7%	0.7 x	0.5 x	64.8%	69.0%	NM	NM	NM	NM	NM	NM
Signify Health	13.82	8.2%	4.5%	(18.2%)	(45.5%)	IPO	(2.8%)	2,346	2,366	923	20.7%	19.1%	2.6 x	2.2 x	50.5%	51.3%	22.0%	23.4%	11.6 x	9.2 x	40.6 x	26.5 x
Tabula Rasa HealthCare	9.44 25.43	0.4%	(38.5%)	(34.4%)	(73.6%)	(83.1%)	(37.1%)	246	585	368 545	11.3%	12.4% 12.2%	1.6 x 2.8 x	1.4 x 2.5 x	29.9%	31.2%	6.8%	8.1%	23.3 x	17.5 x	NM	NM 12.1 v
Tivity Health		0.4%	1.9%	(8.2%)	15.4%	2.8%	(3.8%)	1,277	1,543	545	13.4%		-	-	40.0%	37.5%	29.6%	27.8%	9.6 x	9.1 x	14.1 x	13.1 x
	Mean	(0.9%)	(17.1%)	(25.3%)	(44.0%)	(56.8%)	(23.1%)				7.2%	17.3%	2.2 x	2.0 x	58.2%	58.9%	27.0%	27.8%	11.7 x	8.8 x	18.2 x	13.5 x
	Median	0.4%	(8.6%)	(18.2%)	(45.5%)	(72.1%)	(15.3%)				11.4%	14.1%	1.7 x	1.5 x	50.5%	51.3%	24.9%	25.6%	9.6 x	8.7 x	16.6 x	13.4 x
Employer-Health Tech																						
Accolade	\$21.39	14.4%	11.8%	(41.6%)	(53.2%)	(59.1%)	(18.9%)	\$1,466	\$1,381	\$362	39.8%	25.1%	3.8 x	3.0 x	NA	NA	NM	NM	NM	NM	NM	NM
Benefitfocus	10.19	(0.5%)	(3.1%)	(6.7%)	(15.8%)	(35.2%)	(4.4%)	351	442	255	(1.0%)	3.5%	1.7 x	1.7 x	55.5%	55.6%	17.7%	17.9%	9.8 x	9.3 x	NM	NM
Castlight Health	2.04	0.0%	0.5%	16.6%	7.4%	6.3%	32.5%	334	268	145	3.4%	4.7%	1.8 x	1.8 x	67.8%	71.2%	1.6%	4.6%	NM	38.4 x	NM	NM
HealthEquity	57.55	9.0%	16.2%	(17.2%)	(19.9%)	(33.2%)	30.1%	4,691	4,972	829	10.3%	7.6%	6.0 x	5.6 x	57.1%	59.0%	32.0%	33.3%	18.8 x	16.7 x	38.9 x	33.3 x
Progyny	40.80	9.9%	(11.4%)	(34.4%)	(11.1%)	(16.4%)	(19.0%)	3,692	3,578	763	50.2%	40.8%	4.7 x	3.3 x	23.9%	24.8%	14.5%	15.8%	32.2 x	21.1 x	72.2 x	45.8 x
Sharecare	3.45	5.8%	(14.6%)	(56.4%)	(54.0%)	IPO	(23.2%)	1,166	901	555	33.9%	20.9%	1.6 x	1.3 x	52.3%	54.0%	10.2%	13.4%	15.8 x	10.0 x	NM	23.0 x
	Mean	6.4%	(0.1%)	(23.3%)	(24.4%)	(27.5%)	(0.5%)				22.8%	17.1%	3.3 x	2.8 x	51.3%	52.9%	15.2%	17.0%	19.1 x	19.1 x	55.5 x	34.0 x
	Median	7.4%	(1.3%)	(25.8%)	(17.8%)	(33.2%)	(11.6%)				22.1%	14.3%	2.8 x	2.4 x	55.5%	55.6%	14.5%	15.8%	17.3 x	16.7 x	55.5 x	33.3 x
Provider-Tech																						
Allscripts	\$21.50	3.6%	21.3%	41.3%	26.1%	21.5%	16.5%	\$2,629	\$2,788	\$1,536	2.1%	2.0%	1.8 x	1.8 x	42.3%	42.6%	20.5%	21.8%	8.8 x	8.1 x	20.4 x	18.5 x
Cerner Corporation	92.23	0.6%	(0.1%)	24.0%	16.6%	16.7%	(0.7%)	27,048	28,127	6,094	5.0%	5.6%	4.6 x	4.4 x	83.0%	83.3%	33.8%	34.9%	13.6 x	12.5 x	24.9 x	22.1 x
CPSi	28.05	1.0%	(4.7%)	(16.2%)	(17.6%)	(14.5%)	(4.3%)	402	500	296	6.9%	10.2%	4.0 x	1.5 x	51.4%	52.1%	20.2%	19.5%	8.4 x	7.9 x	10.1 x	8.6 x
Covetrus	17.99	2.6%	2.2%	0.3%	(22.5%)	IPO	(9.9%)	2,519	3,428	4,878	6.4%	6.4%	0.7 x	0.7 x	19.0%	19.2%	5.6%	5.9%	12.5 x	11.2 x	16.8 x	14.4 x
Craneware	24.13	(8.4%)	(25.1%)	(26.7%)	(26.9%)	(20.8%)	(26.5%)	857	627	179	44.9%	7.2%	3.5 x	3.3 x	NA	NA	29.4%	30.3%	11.9 x	10.8 x	26.9 x	25.8 x
Definitive Healthcare	24.77	12.5%	2.1%	(37.1%)	IPO	IPO	(9.4%)	2,516	3,189	208	26.2%	24.7%	15.4 x	12.3 x	87.8%	88.5%	32.1%	37.0%	47.9 x	33.3 x	NM	57.6 x
Health Catalyst	30.22	7.9%	(9.8%)	(37.9%)	(44.7%)	(42.8%)	(23.7%)	1,572	1,295	291	21.3%	22.4%	4.4 x	3.6 x	54.2%	56.1%	NM	3.0%	NM	NM	NM	NM
HealthStream	23.75	(0.8%)	(8.5%)	(12.4%)	(21.3%)	(4.0%)	(9.9%)	759	698	274	6.7%	9.3%	2.5 x	2.3 x	65.3%	65.8%	19.4%	17.1%	13.1 x	13.6 x	NM	NM
ModivCare	109.25	(1.1%)	(18.6%)	(28.5%)	(39.1%)	(39.0%)	(26.3%)	1,526	2,375	2,357	19.2%	7.9%	1.0 x	0.9 x	18.0%	17.8%	8.8%	9.3%	11.4 x	10.0 x	15.4 x	12.1 x
NextGen Healthcare	18.87	0.6%	4.1%	12.9%	21.7%	(5.0%)	6.1%	1,228	1,178	616	8.0%	2.6%	1.9 x	1.9 x	NA	NA	18.7%	19.2%	10.2 x	9.7 x	19.0 x	17.5 x
Phreesia	33.25	13.8%	(5.7%)	(54.3%)	(49.6%)	(57.4%)	(20.2%)	1,704	1,313	264	24.8%	24.1%	5.0 x	4.0 x	63.7%	66.1%	NM	NM	NM	NM	NM	NM
Premier	37.46	(0.1%)	(5.9%)	(7.9%)	4.2%	7.2%	(9.0%)	4,507	4,899	1,377	(13.6%)	6.4%	3.6 x	3.3 x	NA	NA	34.7%	37.0%	10.2 x	9.0 x	15.4 x	13.4 x
Omnicell	152.59	0.5%	(6.6%)	(14.7%)	0.1%	15.5%	(15.4%)	6,927	6,928	1,293	14.2%	13.6%	5.4 x	4.7 x	50.2%	50.9%	21.7%	23.0%	24.6 x	20.6 x	36.5 x	32.9 x
R1 RCM	25.27	8.2%	9.9%	(0.1%)	27.9%	(13.9%)	(0.9%)	6,978	7,616	1,695	14.9%	13.8%	4.5 x	3.9 x	29.8%	30.7%	23.7%	24.5%	19.0 x	16.1 x	42.5 x	33.7 x
Vocera Communications	79.16	0.4%	0.2%	35.1%	75.7%	82.6%	22.1%	2,767	2,722	265	14.0%	12.5%	10.3 x	9.1 x	68.8%	67.0%	17.7%	19.2%	NM	47.4 x	NM	NM
	Mean	2.7%	(3.0%)	(8.1%)	(3.5%)	(4.1%)	(7.4%)				13.4%	11.2%	4.4 x	3.9 x	52.8%	53.3%	22.0%	21.5%	16.0 x	16.2 x	22.8 x	23.3 x
	Median	0.6%	(4.7%)	(12.4%)	(8.8%)	(5.0%)	(9.4%)				14.0%	9.3%	3.6 x	3.3 x	52.8%	54.1%	20.5%	20.7%	12.2 x	11.2 x	19.7 x	18.5 x
Dhamma Taab																						
Pharma-Tech	A07 /5	0.70	0.401	(00.00)	(4.00())	(00.40/)	(0.40())	64 440	64 000	****	00.50	45.001	44.0.	40.0	04.40	04.00%	00.001	07.004	00.0	07.0	50.0	40.0
Certara	\$27.45	6.7%	6.4%	(30.9%)	(1.6%)	(28.1%)	(3.4%)	\$4,418	\$4,298	\$363	23.5%	15.0%	11.8 x	10.3 x	64.1%	64.2%	36.6%	37.9%	32.3 x	27.2 x	53.8 x	42.9 x
IQVIA OptimizeRx	250.43 46.51	0.1% 10.2%	(2.6%) (12.8%)	(0.7%) (45.8%)	1.2% (25.2%)	31.8% (13.9%)	(11.2%) (25.1%)	47,842 841	58,478 756	14,902 82	7.7% 34.2%	10.2% 57.5%	3.9 x 9.2 x	3.6 x 5.9 x	34.1% 57.4%	34.4% 59.0%	22.4% 17.5%	22.7% 23.2%	17.5 x NM	15.7 x 25.2 x	24.7 x 59.6 x	21.6 x 35.4 x
Science 37	9.23	10.2%	(12.8%)	(/	(25.2%) IPO	(13.9%) IPO	(25.1%)	1,053	1,188	105	34.2% 93.9%	57.5% 75.9%	9.2 x 11.3 x	5.9 x 6.4 x	57.4% 44.6%	59.0% 49.9%	17.5% NM	23.2% NM	NM	25.2 X NM	59.6 X	35.4 x NM
Veeva Systems	9.23	2.0%	(11.9%)	(27.9%) (25.6%)	(27.0%)	(24.9%)	(26.0%)	35,912	33,560	2,164	93.9% 17.3%	75.9% 16.8%	11.3 x 15.5 x	6.4 x 13.3 x	44.6% 74.6%	49.9% 75.0%	39.1%	39.8%	39.6 x	33.4 x	58.6 x	50.4 x
veeva oysiems			, ,	, ,	. ,	,	. ,	30,912	33,000	2,104												
	Mean Median	7.0%	(4.7%)	(26.2%)	(13.2%)	(8.8%)	(14.9%)				35.3%	35.1%	10.4 x	7.9 x 6.4 x	55.0% 57.4%	56.5%	28.9%	30.9% 30.5%	29.8 x 32.3 x	25.4 x	49.2 x	37.6 x
	wealan	6.7%	(2.6%)	(27.9%)	(13.4%)	(19.4%)	(11.2%)				23.5%	16.8%	11.3 x	0.4 X	57.4%	59.0%	29.5%	30.5%	3∠.3 X	26.2 x	56.2 x	39.1 x

Source: Capital IQ and Public filings.

Note: Revenue, EBITDA, P/E multiples and EBITDA margins denoted as 'NM' if negative, or greater than 25.0x, 50.0x and 75.0x, respectively. Enterprise Value includes non-controlling interest and preferred equity. Amounts presented in USD, Millions Except Per Share data.



Source: Capital IQ and Public filings.

Note: Revenue, EBITDA, P/E multiples and EBITDA margins denoted as 'NM' if negative, or greater than 25.0x, 50.0x and 75.0x, respectively. Enterprise Value includes non-controlling interest and preferred equity. Amounts presented in USD, Millions Except Per Share data.

a) Healthcare Tech Public Comps is defined as all companies included on pages 6 and 7.





End Markets and Consolidators

	Price	Stock Price Performance			e		Equity	Enterprise	Revenue	nue % Rev Growth		EV / Re	venue	Gross	Margin	EBITDA	Margin	EV / EBITDA		Price	/ EPS	
Company Name	2/10/22	Weekly	1-Month	3-Month	6-Month	LTM	YTD	Value	Value	CY2022	CY2021	CY2022	CY2022	CY2023	CY2022	CY2023	CY2022	CY2023	CY2022	CY2023	CY2022	CY2023
Large Cap-Payers																						
Anthem	\$457.60	1.3%	4.5%	7.7%	21.3%	53.5%	(1.3%)	\$111,066	\$129,285	\$152,100	10.6%	6.0%	0.9 x	0.8 x	25.1%	25.2%	7.2%	7.5%	11.8 x	10.7 x	16.1 x	14.2 x
Centene	84.15	3.2%	8.1%	12.1%	29.5%	37.8%	2.1%	49,016	54,963	137,097	8.8%	1.7%	0.4 x	0.4 x	17.7%	17.8%	4.1%	4.5%	9.8 x	8.7 x	15.6 x	13.4 x
Cigna	230.27	5.8%	(1.5%)	5.7%	9.2%	9.0%	0.3%	76,318	104,979	178,686	3.7%	5.7%	0.6 x	0.6 x	13.9%	14.2%	6.4%	6.4%	9.1 x	8.6 x	10.2 x	9.2 x
Humana	432.17	1.4%	12.2%	(3.6%)	4.2%	14.3%	(6.8%)	55,664	65,113	92,430	10.9%	8.4%	0.7 x	0.7 x	19.4%	19.2%	5.4%	5.4%	13.1 x	12.0 x	17.9 x	15.9 x
Molina Healthcare	306.16	2.9%	5.7%	1.1%	19.6%	48.5%	(3.7%)	17,757	15,711	30,705	11.6%	4.5%	0.5 x	0.5 x	14.8%	14.8%	4.9%	5.2%	10.5 x	9.4 x	18.0 x	16.0 x
UnitedHealth Group	486.72	(0.4%)	4.7%	5.8%	18.2%	46.0%	(3.1%)	458,418	484,480	319,282	11.3%	8.6%	1.5 x	1.4 x	24.3%	24.5%	9.5%	9.8%	15.9 x	14.2 x	22.6 x	19.7 x
	Mean	2.4%	5.6%	4.8%	17.0%	34.9%	(2.1%)				9.5%	5.8%	0.8 x	0.7 x	19.2%		6.2%	6.5%	11.7 x	10.6 x	16.7 x	14.7 x
	Median	2.1%	5.2%	5.8%	18.9%	41.9%	(2.2%)				10.8%	5.9%	0.6 x	0.6 x	18.5%	18.5%	5.9%	5.9%	11.2 x	10.0 x	17.0 x	15.0 x
.																						
Providers Acadia Healthcare	650.00	0.70/	(4.00())	(47.00()	(40.00())	(0.50())	(40.00())	¢4.004	60 404	¢0.470	7.00/	7.2%	0.5	0.0			00 70/	04.00/	10.1	0.0	10.4	40.4.
	\$52.90	0.7%	(4.9%)	(17.6%)	(16.2%)	(0.5%)	(12.9%)	\$4,801	\$6,124	\$2,478	7.3% 3.0%	3.2%	2.5 x	2.3 x	NA	NA	23.7%	24.0%	10.4 x	9.6 x	18.1 x	16.4 x
Community Health Systems DaVita HealthCare Partners	13.29	4.6%	5.2%	(9.9%)	5.6%	42.0%	(0.2%)	1,690 11.358	12,983	12,620 11,908	3.0%	3.2% 5.1%	1.0 x 1.7 x	1.0 x	NA 30.7%	NA 31.3%	14.5% 19.8%	14.8% 21.3%	7.1 x	6.8 x 7.8 x	9.8 x 13.6 x	7.2 x
	111.46	1.4%	(2.0%)	4.8%	(16.0%)	(1.7%)	(2.0%)	1	20,826	1	2.7%	5.1%	1.7 x 1.8 x	1.7 x 1.7 x	30.7%		21.0%	21.3%	8.8 x 8.6 x	7.8 x 8.2 x	13.6 x 12.8 x	10.9 x
HCA Holdings MEDNAX	240.01 24.51	(0.4%) (0.6%)		(2.1%)	(0.3%) (26.0%)	37.3%	(6.6%)	74,649 2.089	110,199 2.638	61,086 1,965	3.4%	5.8%	1.6 x 1.3 x	1.7 x 1.3 x	28.3%		21.0%	20.8%	0.0 x 9.7 x	0.2 x 9.1 x	12.0 x 14.2 x	11.7 x 12.8 x
Tenet Healthcare	84.99	13.0%	(8.3%) 14.0%	(13.9%) 6.3%	30.2%	(11.4%) 71.2%	(9.9%) 4.0%	2,089	2,636	1965	0.7%	5.6%	1.3 x	1.3 x 1.2 x	20.3% NA	20.0% NA	17.6%	17.8%	9.7 x	6.9 x	14.2 x 13.0 x	12.0 X
Universal Health Services	133.57	1.6%	0.5%	3.2%	(9.2%)	2.4%	4.0%	10.998	25,616	19,700	2.8%	5.0%	1.3 x 1.1 x	1.2 x	NA	NA	14.9%	17.8%	7.4 x 7.6 x	0.9 x 7.2 x	10.9 x	9.9 x
Universal riealth Gervices		-		-	. ,			10,330	14,001	12,040							-		-			
	Mean Median	2.9% 1.4%	0.1% (2.0%)	(4.2%) (2.1%)	(4.6%) (9.2%)	19.9% 2.4%	(3.5%) (2.0%)				3.4% 3.0%	5.3% 5.1%	1.5 x 1.3 x	1.5 x 1.3 x	32.5% 30.7%		17.9% 17.6%	18.2% 17.8%	8.5 x 8.6 x	7.9 x 7.8 x	13.2 x 13.0 x	11.5 x 11.6 x
	Weulan	1.4 /0	(2.0%)	(2.170)	(9.270)	2.4 /0	(2.0 %)				3.0 /6	5.1/0	1.3 X	1.3 X	30.7 /6	31.3 /0	17.0 /0	17.0%	0.0 X	7.0 X	13.0 X	11.0 X
PBMs / Distributors																						
AmerisourceBergen	\$141.54	2.7%	5.1%	12.6%	19.0%	33.2%	6.5%	\$29,601	\$33,473	\$240,473	9.7%	5.4%	0.1 x	0.1 x	NA	NA	1.5%	1.4%	9.4 x	9.1 x	12.9 x	12.0 x
Cardinal Health	52.81	2.7%	3.5%	5.0%	3.5%	(0.5%)	2.6%	14,632	17,118	182,108	8.3%	4.8%	0.1 x	0.1 x	NA	NA	1.4%	1.5%	6.6 x	6.2 x	9.6 x	8.6 x
CVS Health	105.32	(3.1%)	0.2%	13.3%	26.5%	42.7%	2.1%	138,234	182,191	307,360	5.6%	4.5%	0.6 x	0.6 x	17.5%	17.3%	6.4%	6.4%	9.2 x	8.8 x	12.7 x	11.7 x
Henry Schein	76.31	0.2%	(3.6%)	(2.4%)	1.0%	7.9%	(1.6%)	10,618	12,534	12,522	2.5%	3.8%	1.0 x	1.0 x	29.6%	29.7%	8.8%	8.8%	11.4 x	11.0 x	16.5 x	15.3 x
McKesson	273.53	2.3%	9.1%	24.5%	40.2%	48.6%	10.0%	40,974	45,121	255,548	1.8%	1.4%	0.2 x	0.2 x	NA	NA	2.0%	2.0%	8.9 x	8.8 x	12.1 x	11.2 x
Owens & Minor	41.82	(0.4%)	(7.8%)	(0.3%)	9.0%	44.8%	(3.9%)	3,156	4,077	9,549	(2.0%)	5.8%	0.4 x	0.4 x	15.4%	15.5%	4.6%	4.9%	9.2 x	8.3 x	12.3 x	11.0 x
Patterson Companies	27.88	(0.2%)	(4.5%)	(16.5%)	(3.8%)	(14.7%)	(5.0%)	2,753	3,239	6,543	5.6%	3.6%	0.5 x	0.5 x	NA	NA	5.2%	5.1%	9.5 x	9.4 x	12.9 x	12.2 x
Walgreens Boots Alliance	49.25	(0.5%)	(8.3%)	0.6%	1.7%	(4.6%)	(5.6%)	43,155	60,982	131,914	(0.2%)	3.7%	0.5 x	0.4 x	NA	NA	4.8%	5.0%	9.6 x	9.0 x	10.5 x	9.4 x
	Mean	0.5%	(0.8%)	4.6%	12.1%	19.7%	0.6%				3.9%	4.1%	0.4 x	0.4 x	20.8%	20.8%	4.3%	4.4%	9.2 x	8.8 x	12.4 x	11.4 x
	Median	0.0%	(1.7%)	2.8%	6.3%	20.5%	0.3%				4.0%	4.2%	0.4 x	0.4 x	17.5%	17.3%	4.7%	4.9%	9.3 x	8.9 x	12.5 x	11.5 x



End Markets and Consolidators (Cont'd)

	Price	Stock Price Per			rice Performance		Equity	Enterprise	Revenue	% Rev 0	% Rev Growth EV / Revenue		Gross	Margin	EBITDA Margin		EV / EBITDA		Price / EPS			
Company Name	2/10/22	Weekly	1-Month	3-Month	6-Month	LTM	YTD	Value	Value	CY2022	CY2021	CY2022	CY2022	CY2023	CY2022	CY2023	CY2022	CY2023	CY2022	CY2023	CY2022	CY2023
Information Services																						
Equifax	\$231.17	(1.0%)	(11.4%)	(16.6%)	(10.8%)	26.3%	(21.0%)	\$28,226	\$33,313	\$5,338	8.5%	9.0%	6.2 x	5.7 x	60.9%	61.8%	36.0%	37.5%	17.3 x	15.2 x	26.4 x	22.5 x
Experian	41.38	(1.5%)	(5.6%)	(11.7%)	(3.4%)	18.0%	(15.9%)	37,811	42,237	6,561	11.3%	10.5%	6.4 x	5.8 x	NA	NA	35.9%	35.7%	18.0 x	16.3 x	30.2 x	27.1 x
Fair Isaac	516.82	4.4%	17.4%	33.0%	12.5%	9.5%	19.2%	13,582	15,053	1,412	6.9%	9.3%	10.7 x	9.8 x	NA	NA	46.6%	48.0%	22.9 x	20.3 x	31.8 x	26.4 x
RELX	30.91	0.1%	4.1%	(2.9%)	4.7%	25.9%	(5.0%)	59,613	67,856	10,926	10.7%	6.5%	6.2 x	5.8 x	64.2%	64.4%	37.7%	38.4%	16.5 x	15.2 x	22.6 x	20.6 x
TransUnion	103.90	3.4%	(5.0%)	(7.8%)	(12.5%)	12.1%	(12.4%)	19,907	22,673	3,794	21.1%	8.7%	6.0 x	5.5 x	65.3%	65.4%	37.7%	38.9%	15.8 x	14.1 x	25.8 x	22.3 x
Verisk Analytics	194.91	(1.0%)	(5.7%)	(8.8%)	4.0%	2.1%	(14.8%)	32,081	34,903	3,210	7.0%	6.7%	10.9 x	10.2 x	64.3%	65.0%	49.0%	49.4%	22.2 x	20.6 x	32.6 x	29.5 x
Wolters Kluwer	101.92	(0.9%)	(5.5%)	(6.9%)	(8.7%)	22.5%	(13.5%)	26,347	29,123	5,708	5.6%	4.7%	5.1 x	4.9 x	70.0%	70.0%	32.2%	32.5%	15.8 x	15.0 x	24.6 x	22.8 x
WPP	16.69	5.5%	6.5%	11.8%	22.0%	48.6%	10.1%	19,001	24,362	14,864	5.1%	3.2%	1.6 x	1.6 x	28.1%	22.5%	18.3%	19.3%	8.9 x	8.3 x	13.8 x	12.2 x
	Mean	1.1%	(0.6%)	(1.2%)	1.0%	20.6%	(6.7%)				9.5%	7.3%	6.6 x	6.2 x	58.8%	58.2%	36.7%	37.5%	17.2 x	15.6 x	26.0 x	22.9 x
	Median	(0.4%)	(5.3%)	(7.3%)	0.3%	20.2%	(12.9%)				7.7%	7.7%	6.2 x	5.8 x	64.2%	64.7%	36.8%	38.0%	16.9 x	15.2 x	26.1 x	22.6 x
Technology																						
Alphabet	\$2.773.15	(2.8%)	0.1%	(5.4%)	0.4%	32.3%	(1 20/)	\$1.870.888	\$1,746,169	\$303.508	19.4%	15.7%	5.8 x	5.0 x	56.7%	57.0%	40.1%	40.0%	14.4 x	12.4 x	24.1 x	20.8 x
Apple	172.19	(2.6%)	0.1%	16.4%	18.3%	27.2%	(4.2 %)	2.876.791	2.796.993	403.321	13.8%	6.8%	6.9 x	6.5 x	NA	NA	33.0%	31.9%	21.0 x	20.3 x	24.1 X	
Citrix Systems	102.14	(0.1%)	5.1%	14.7%	1.3%	(25.4%)	8.0%	12,775	15.575	3.314	3.7%	5.4%	4.7 x	4.5 x	84.0%	84.1%	31.6%	32.0%	14.9 x	13.9 x	19.8 x	
DXC Technology	37.81	8.3%	14.9%	12.6%	(6.6%)	47.1%	17.5%	9.244	11,582	16,340	(1.6%)	0.5%	0.7 x	4.3 x	NA	NA	16.4%	17.4%	4.3 x	4.0 x	9.3 x	
Hewlett Packard	17.35	3.0%	2.1%	10.4%	17.1%	24.3%	10.0%	22,441	32,822	28,787	3.1%	3.7%	1.1 x	1.1 x	NA	NA	19.7%	19.9%	4.5 x	4.0 x	8.3 x	
Intel	48.87	1.2%	(11.5%)	(3.7%)	(9.4%)	(17.0%)	(5.1%)	203,234	210,816	75.400	2.6%	2.8%	2.8 x	2.7 x	52.0%	52.2%	39.4%	41.3%	7.1 x	6.6 x	14.1 x	
Microsoft	302.67	0.5%	(3.7%)	(8.5%)	5.7%	24.6%	(10.0%)	2,333,100	2,275,205	212,654	18.1%	14.6%	10.7 x	9.3 x	NA	NA	50.0%	51.2%	21.4 x	18.2 x	30.7 x	
Oracle	81.85	(0.1%)	(8.3%)	(12.8%)	(8.7%)	29.4%	(6.1%)	218,576	274,612	43,269	5.2%	3.9%	6.3 x	6.1 x	NA	NA	49.5%	51.5%	12.8 x	11.9 x	16.4 x	
salesforce.com	217.67	2.3%	(5.2%)	(27.4%)	(10.6%)	(8.0%)	(14.3%)	214,405	215,942	31,767	20.3%	18.1%	6.8 x	5.8 x	79.0%	79.1%	31.5%	30.6%	21.6 x	18.8 x	46.8 x	
Samsung Electronics	63.13	3.4%	(2.9%)	6.2%	(9.3%)	(14.4%)	(4.0%)	424,394	335,803	261,526	11.6%	7.1%	1.3 x	1.2 x	41.4%	42.5%	31.1%	32.6%	4.1 x	3.7 x	10.9 x	9.3 x
SAP	125.56	0.7%	(8.2%)	(14.7%)	(13.8%)	(3.5%)	(11.6%)	147,997	155,554	33,999	8.2%	6.3%	4.6 x	4.3 x	72.9%	73.9%	33.8%	34.5%	13.6 x	12.5 x	20.6 x	
Workday	240.02	3.0%	(4.9%)	(17.5%)	4.0%	(12.4%)	(12.1%)	60,863	59,156	6,105	19.1%	19.7%	9.7 x	8.1 x	77.7%	78.4%	24.4%	25.5%	39.7 x	31.8 x	68.3 x	
	Mean	1.6%	(1.9%)	(2.5%)	(1.0%)	8.7%	(2.9%)				10.3%	8.7%	5.1 x	4.6 x	66.2%	66.7%	33.4%	34.0%	15.1 x	13.3 x	24.7 x	21.2 x
	Median	0.9%	(3.3%)	(4.6%)	(3.1%)	10.4%	(4.6%)				9.9%	6.6%	5.2 x	4.7 x	72.9%	73.9%	32.3%	32.3%	14.0 x	12.4 x	20.2 x	18.1 x
Brokers																						
Aon	\$287.28	3.9%	1.9%	(3.5%)	7.5%	26.8%	(4.4%)	\$61.708	\$70.361	\$12.951	5.8%	4.7%	5.4 x	5.2 x	NA	NA	31.6%	32.3%	17.2 x	16.0 x	21.8 x	19.6 x
Arthur J. Gallagher & Co.	158.81	2.8%	(2.2%)	(1.5%)	12.7%	35.5%	(6.4%)	33,105	39,037	8,562	6.4%	9.5%	4.6 x	4.2 x	NA	NA	31.5%	32.4%	14.5 x	12.8 x	26.2 x	
Marsh & McLennan Companies	153.51	1.0%	(7.1%)	(7.0%)	2.1%	36.2%	(11.7%)	77,506	86,704	21,093	7.6%	6.4%	4.1 x	3.9 x	NA	NA	26.1%	26.5%	15.7 x	14.6 x	22.9 x	
Willis Towers Watson	226.64	(3.3%)	(2.6%)	(2.0%)	3.9%	0.4%	(4.6%)	27,904	27,853	9,424	(0.9%)	4.6%	3.0 x	2.8 x	NA	NA	26.6%	27.5%	11.1 x	10.3 x	16.5 x	
	Mean	1.1%	(2.5%)	(3.5%)	6.6%	24.7%	(6.8%)				4.7%	6.3%	4.3 x	4.0 x	NA	NA	29.0%	29.7%	14.6 x	13.4 x	21.9 x	19.3 x
	Median	1.9%	(2.4%)	(2.8%)	5.7%	31.2%	(5.5%)				6.1%	5.6%	4.3 x	4.0 x	NA	NA	29.1%		15.1 x	13.7 x	22.4 x	
			(=,0)	(=== ,0)			(,0)				/0	/0					/0	/0				



End Markets and Consolidators (Cont'd)

	Price	Stock P			Performanc	e		Equity	Enterprise	Revenue	% Rev	Growth	EV / Re	evenue	Gross	Margin	EBITDA	A Margin	EV / E	BITDA	Price / EPS	
Company Name	2/10/22	Weekly	1-Month	3-Month	6-Month	LTM	YTD	Value	Value	CY2022	CY2021	CY2022	CY2022	CY2023	CY2022	CY2023	CY2022	CY2023	CY2022	CY2023	CY2022	CY2023
BPO / Systems Integrations																						
Accenture	\$342.39	(0.9%)	(8.2%)	(6.1%)	6.9%	33.3%	(17.4%)	\$216,391	\$211,397	\$61,080	16.9%	8.7%	3.5 x	3.2 x	NA	NA	18.8%	19.0%	18.4 x	16.8 x	31.8 x	28.4 x
CBIZ	38.29	(0.4%)	(0.2%)	(2.4%)	16.2%	39.2%	(2.1%)	1,980	2,167	1,317	20.2%	3.5%	1.6 x	1.6 x	15.3%	16.5%	13.7%	14.4%	12.0 x	11.0 x	19.1 x	17.0 x
Cognizant	90.25	4.9%	4.1%	11.9%	23.5%	18.7%	1.7%	48,160	46,105	20,281	9.6%	8.7%	2.3 x	2.1 x	37.4%	37.4%	18.7%	19.0%	12.2 x	11.0 x	19.8 x	17.8 x
Conduent	4.59	0.2%	(22.3%)	(22.3%)	(33.4%)	(14.7%)	(14.0%)	1,021	2,174	4,125	(0.2%)	0.9%	0.5 x	0.5 x	24.0%	24.5%	11.5%	11.8%	4.6 x	4.4 x	7.8 x	7.1 x
ExIService	121.41	0.0%	(8.1%)	(9.4%)	2.6%	41.0%	(16.1%)	4,166	4,067	1,244	11.3%	9.9%	3.3 x	3.0 x	37.9%	37.9%	20.9%	21.1%	15.6 x	14.1 x	24.4 x	21.8 x
Fidelity National	113.69	(1.5%)	(2.3%)	(4.0%)	(14.2%)	(14.7%)	4.2%	69,230	87,808	14,905	7.2%	7.7%	5.9 x	5.5 x	37.9%	38.1%	44.8%	46.0%	13.2 x	11.9 x	15.6 x	13.8 x
Firstsource Solutions	2.00	(8.2%)	(18.4%)	(17.2%)	(20.9%)	48.4%	(18.5%)	1,366	1,505	853	9.1%	12.1%	1.8 x	1.6 x	NA	NA	16.4%	16.4%	10.8 x	9.6 x	17.6 x	15.5 x
Gartner	291.12	0.4%	(0.9%)	(11.7%)	(0.2%)	61.2%	(12.9%)	24,910	26,678	5,256	12.4%	13.0%	5.1 x	4.5 x	67.6%	67.4%	20.0%	20.2%	25.4 x	22.2 x	42.1 x	35.3 x
Genpact	48.35	(1.5%)	(7.2%)	(3.4%)	(5.3%)	14.4%	(8.9%)	9,093	9,871	4,393	10.0%	10.0%	2.2 x	2.0 x	35.8%	35.8%	18.9%	19.0%	11.9 x	10.7 x	17.9 x	15.9 x
Huron Consulting Group	43.59	(1.4%)	(9.3%)	(17.3%)	(7.2%)	(23.5%)	(12.6%)	910	1,164	964	7.9%	7.7%	1.2 x	1.1 x	30.8%	30.3%	11.6%	12.1%	10.4 x	9.2 x	14.8 x	12.7 x
Infosys	22.94	0.8%	(7.4%)	(0.1%)	0.7%	31.1%	(9.4%)	98,776	96,854	17,653	14.9%	8.5%	5.5 x	5.1 x	NA	NA	26.0%	25.2%	21.1 x	20.1 x	29.0 x	25.6 x
Leidos	87.77	(2.5%)	(2.2%)	(6.6%)	(7.2%)	(19.7%)	(1.3%)	12,318	16,952	14,475	5.1%	4.9%	1.2 x	1.1 x	14.5%	14.7%	10.5%	10.5%	11.1 x	10.6 x	12.7 x	11.8 x
MAXIMUS	74.98	(1.3%)	(4.9%)	(12.8%)	(8.0%)	(10.8%)	(5.9%)	4,643	6,052	4,597	11.5%	1.9%	1.3 x	1.3 x	NA	NA	11.4%	NA	11.6 x	NA	16.3 x	13.5 x
Tata Consultancy	50.21	(1.9%)	(4.1%)	7.1%	12.2%	13.8%	0.1%	185,742	179,121	27,345	10.0%	7.3%	6.6 x	6.1 x	NA	NA	27.2%	26.4%	24.1 x	23.1 x	33.1 x	32.3 x
Tech Mahindra	19.56	0.4%	(15.6%)	(7.3%)	10.1%	46.1%	(18.6%)	17,145	16,035	6,454	14.6%	7.4%	2.5 x	2.3 x	NA	NA	18.3%	17.9%	13.6 x	12.9 x	20.8 x	20.7 x
TeleTech	75.81	1.0%	(10.8%)	(18.1%)	(26.4%)	(13.3%)	(16.3%)	3,637	4,371	2,484	10.2%	8.3%	1.8 x	1.6 x	26.4%	26.4%	15.7%	16.0%	11.2 x	10.2 x	15.5 x	13.9 x
WEX	168.96	7.7%	11.5%	11.8%	(4.0%)	(21.2%)	20.4%	7,573	9,140	2,072	12.4%	10.0%	4.4 x	4.0 x	64.4%	66.0%	39.8%	41.8%	11.1 x	9.6 x	14.9 x	13.5 x
WNS	87.80	3.0%	(0.0%)	0.3%	7.5%	17.2%	(0.5%)	4,287	4,193	1,102	15.4%	10.9%	3.8 x	3.4 x	NA	NA	21.9%	24.4%	17.3 x	14.1 x	32.1 x	27.6 x
	Mean	(0.1%)	(5.9%)	(6.0%)	(2.6%)	13.7%	(7.1%)				11.0%	7.9%	3.0 x	2.8 x	35.6%	35.9%	20.3%	21.2%	14.2 x	13.0 x	21.4 x	19.1 x
	Median	(0.2%)	(6.1%)	(6.4%)	(2.1%)	15.8%	(9.1%)				10.7%	8.4%	2.4 x	2.2 x	35.8%	35.8%	18.8%	19.0%	12.1 x	11.0 x	18.5 x	16.5 x
Conglomerates																						
3M Company	\$159.74	(2.8%)	(10.0%)	(12.4%)	(19.8%)	(11.8%)	(10.1%)	\$93,455	\$106.053	\$36.578	3.6%	2.9%	2.9 x	2.8 x	47.2%	47.6%	26.7%	27.2%	10.8 x	10.4 x	15.3 x	14.3 x
Amazon	3,181.75	14.6%	(1.5%)	(8.6%)	(4.2%)	(3.2%)	(4.6%)	1,640,408	1,625,468	539,880	14.7%	17.5%	3.0 x	2.6 x	42.7%	43.6%	15.6%	16.8%	19.3 x	15.3 x	66.2 x	43.1 x
General Electric	98.79	0.5%	(0.6%)	(9.3%)	(6.9%)	8.3%	4.6%	108,438	119,158	78,426	4.2%	7.8%	1.5 x	1.4 x	25.6%	26.8%	12.7%	14.8%	12.0 x	9.6 x	28.6 x	18.0 x
Roper Technologies	442.31	(4.1%)	(2.5%)	(9.0%)	(7.7%)	10.1%	(10.1%)	46.657	54.227	6,163	6.9%	5.5%	8.8 x	8.3 x	67.4%	67.6%	38.5%	38.5%	22.9 x	21.7 x	28.6 x	26.6 x
Royal Philips	34.37	4.2%	(8.9%)	(28,7%)	(22.9%)	(39.5%)	(7.8%)	29.886	35.297	20.856	6.3%	7.2%	1.7 x	1.6 x	45.5%	47.8%	17.7%	18.3%	9.6 x	8.6 x	15.9 x	13.5 x
Siemens	32.53	(0.4%)	4.1%	1.1%	17.6%	27.4%	2.6%	11.584	10.922	2.214	24.4%	16.2%	4.9 x	4.2 x	NA	NA	11.9%	12.3%	41.4 x	34.5 x	58.2 x	48.3 x
Walmart	136.08	(3.5%)	(5.9%)	(8.3%)	(8.5%)	(5.6%)	(6.0%)	377,469	413,738	585,676	3.3%	3.0%	0.7 x	0.7 x	24.3%	24.4%	6.5%	6.6%	10.9 x	10.4 x	20.2 x	18.8 x
	Mean	1.2%	(3.6%)	(10.8%)	(7.5%)	(2.1%)	(4.5%)				9.1%	8.6%	3.4 x	3.1 x	42.1%	43.0%	18.5%	19.2%	18.1 x	15.8 x	33.3 x	26.1 x
	Median	(0.4%)	(2.5%)	(9.0%)	(7.7%)	(3.2%)	(6.0%)				6.3%	7.2%	2.9 x	2.6 x	44.1%	45.6%	15.6%	16.8%	12.0 x	10.4 x	28.6 x	18.8 x
Market Statistics																						
S&P 500	\$4,504.08	0.6%	(3.6%)	(3.1%)	1.5%	15.2%	(5.5%)															
NASDAQ Composite Index	14,309.20	3.1%	(4.2%)	(8.4%)	(3.2%)	2.4%	(8.5%)															-
Russell 2000 Index	2,071.09	4.0%	(4.2%)		(3.2%)	(9.3%)	(8.5%)															
				(13.3%)	. ,																	
Dow Jones Industrial Average	35,241.59	0.4%	(2.3%)	(2.3%)	(0.1%)	12.1%	(3.0%)															

Disclaimer

This document is a marketing presentation. It has been prepared by personnel of Solomon Partners or its affiliates and not by Natixis' research department. It is not investment research or a research recommendation and is not intended to constitute a sufficient basis upon which to make an investment decision. This material is provided for information purposes, is intended for your use only and does not constitute an invitation or offer to subscribe for or purchase any of the products or services mentioned. Any pricing information provided is indicative only and does not represent a level at which an actual trade could be executed. Natixis may trade as principal or have proprietary positions in securities or other financial instruments that are the subject of this material. It is intended only to provide observations and views of the said personnel, which may be different from, or inconsistent with, the observations and views of Natixis analysts or other Natixis sales and/or trading personnel, or the proprietary positions of Natixis. Observations and views of the writer may change at any time without notice.

This presentation may contain forward-looking statements and comments relating to the objectives and strategy of Solomon Partners. Any such projections inherently depend on assumptions, project considerations, objectives and expectations linked to future events, transactions, products and services as well as on suppositions regarding future performance and synergies.

Certain information in this presentation relating to parties other than Solomon Partners or taken from external sources has not been subject to independent verification, and Solomon Partners makes no warranty as to the accuracy, fairness or completeness of the information or opinions in this presentation. Neither Solomon Partners nor its representatives shall be liable for any errors or omissions or for any harm resulting from the use of this presentation, the content of this presentation, or any document or information referred to in this presentation. Nothing in this presentation constitutes investment, legal, accounting or tax advice, or a representation that any investment or strategy is suitable or appropriate to your individual circumstances. Each individual or entity who receives this document or participates in any future transaction shall be responsible for obtaining all such advice as it thinks appropriate on such matters and shall be responsible for making its own independent investigation and appraisal of the risks, benefits and suitability of the transactions as to itself. Any discussions of past performance should not be taken as an indication of future results, and no representation, expressed or implied, is made regarding future results. No person shall have any liability whatsoever (in negligence or otherwise) for any loss arising from any use of this document or its contents or otherwise arising in connection with this document or any other written or oral communications transmitted to the recipient in relation hereto.

Solomon Partners and/or its affiliates, officers, directors and employees, including persons involved in the preparation or issuance of this material, may, from time to time, have long or short positions in, and buy or sell, the securities or derivatives mentioned in this material.

The information contained herein may be based in part on hypothetical assumptions and for certain models, past performance. These assumptions have certain inherent limitations and will be affected by any changes in the structure or assets for this transaction. This material is confidential and any redistribution is prohibited. Solomon Partners is not responsible for any unauthorized redistribution.

